Takeda Submits NDA For Azilsartan With U.S. FDA To Expand Reach In Hypertension Market
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Takeda Pharmaceutical April 28 submitted a new drug application with U.S. FDA for its angiotensin receptor blocker azilsartan and hopes to bank on the global success of candesartan to further its franchise in the hypertension treatment market
You may also be interested in...
Takeda Wins One Loses Another With U.S. FDA Approval Of Edarbi, Japan Withdrawal Of Dasen
TOKYO - Takeda Pharmaceutical Co. is feeling the ups and downs of drug making having announced U.S. FDA approval of the angiotensin II receptor blocker Edarbi days after announcing the withdrawal of its long-time anti-inflammatory drug Dasen from the Japanese market
Takeda Wins One Loses Another With U.S. FDA Approval Of Edarbi, Japan Withdrawal Of Dasen
TOKYO - Takeda Pharmaceutical Co. is feeling the ups and downs of drug making having announced U.S. FDA approval of the angiotensin II receptor blocker Edarbi days after announcing the withdrawal of its long-time anti-inflammatory drug Dasen from the Japanese market
Takeda's Alogliptin Among MHLW Approval Recommendations; Pfizer, Alexion Also Gain
Japan's First Committee on New Drugs at the Ministry of Health, Labor and Welfare recommended for approval three Takeda drugs: alogliptin and pioglitazone/metformin combination - both for type 2 diabetes - and combination drug candesartan/amlodipine for hypertension